Will CROs Take On the Risks of Strategic Outsourcing?

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-06-02-2004, Volume 28, Issue 6

It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.

Related Content:

Bio/Pharma BusinessOutsourcingOutsourcing OutlookContract Manufacturing, GeneralPharmaceutical Technology-06-02-2004
Alexion Completes Purchase and License Agreement of Rare Disease Gene Therapy Portfolio from Pfizer
Genentech Partners with Orionis Biosciences to Discover and Develop Molecular Glue Class Medicines
Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb